CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Love it or raze it?
February 20, 2026
An architectural magazine covered the demolition of UC's Crosley Tower.
Social media linked to student loneliness
February 20, 2026
Inside Higher Education highlighted a new study by the University of Cincinnati that found that college students across the country who spent more time on social media reported feeling more loneliness.
Before the medals: The science behind training for freezing mountain air
February 19, 2026
From freezing temperatures to thin mountain air, University of Cincinnati exercise physiologist Christopher Kotarsky, PhD, explained how cold and altitude impact Olympic performance in a recent WLWT-TV/Ch. 5 news report.